Patents by Inventor Thomas Børglum Kjeldsen

Thomas Børglum Kjeldsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL INSULIN ANALOGUES AND USES THEREOF
    Publication number: 20240141011
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • NOVEL INSULIN ANALOGUES AND USES THEREOF
    Publication number: 20230192801
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Applicants: Novo Nordisk A/S, Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Bifunctional compounds comprising insulin peptides and EGF(A) peptides
    Patent number: 11649269
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: May 16, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • Insulin analogues and uses thereof
    Patent number: 11498951
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: November 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Oligomer extended insulin-Fc conjugates
    Patent number: 11471537
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 18, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • BIFUNCTIONAL COMPOUNDS COMPRISING INSULIN PEPTIDES AND EGF(A) PEPTIDES
    Publication number: 20220009989
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 13, 2022
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • Insulins with polar recombinant extensions
    Patent number: 11208452
    Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson
  • OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE
    Publication number: 20210393745
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to a novel Fc fragment, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 23, 2021
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Zhaosheng Lin, Yuanyuan Zhang, Zhe Wan
  • NOVEL INSULIN ANALOGUES AND USES THEREOF
    Publication number: 20210179685
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 17, 2021
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen
  • Oligomer Extended Insulin-FC Conjugates
    Publication number: 20200261595
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 20, 2020
    Applicant: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES
    Publication number: 20190112348
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 18, 2019
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Protease stabilized acylated insulin analogues
    Patent number: 10259856
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: April 16, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • INSULINS WITH POLAR RECOMBINANT EXTENSIONS
    Publication number: 20180291076
    Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 11, 2018
    Inventors: Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson
  • Insulin derivatives and the medical uses hereof
    Patent number: 10040839
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: August 7, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Susanne Hostrup, Martin Muenzel, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Christian Fledelius
  • Derivative of an insulin analogue
    Patent number: 9896496
    Abstract: The present invention provides a novel derivative of an analogue of human insulin, useful for the treatment of diabetes.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: February 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Tina Moeller Tagmose, Helle Naver, Thomas Boerglum Kjeldsen
  • Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
    Publication number: 20180000742
    Abstract: The present invention relates to a solid oral insulin composition comprising a salt of capric acid which enhances the bioavailability and/or the absorption of said acylated insulin in combination with a polyvinyl alcohol coating, which is soluble in aqueous media independent of pH.
    Type: Application
    Filed: January 29, 2015
    Publication date: January 4, 2018
    Inventors: Lars Hovgaard, Hanne Refsgaard, Thomas Boerglum Kjeldsen, Peter Madsen, Giustino Di Pretoro
  • Novel Insulin Derivatives and the Medical Uses Hereof
    Publication number: 20170008945
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: February 26, 2015
    Publication date: January 12, 2017
    Inventors: Peter Madsen, Susanne Hostrup, Martin Muenzel, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Christian Fledelius
  • Insulin derivatives containing additional disulfide bonds
    Patent number: 9512195
    Abstract: The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: December 6, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Frantisek Hubalek, Thomas Boerglum Kjeldsen, Svend Ludvigsen
  • NOVEL DERIVATIVE OF AN INSULIN ANALOGUE
    Publication number: 20160215037
    Abstract: The present invention provides a novel derivative of an analogue of human insulin, useful for the treatment of diabetes.
    Type: Application
    Filed: October 3, 2014
    Publication date: July 28, 2016
    Inventors: Peter Madsen, Tina Moeller Tagmose, Helle Naver, Thomas Boerglum Kjeldsen
  • Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating
    Publication number: 20160193154
    Abstract: The present invention relates to a solid oral insulin composition comprising a salt of capric acid which enhances the bioavailability and/or the absorption of said insulin in combination with an anionic copolymer coating, which is resistant to dissolution at pH below 5.0 and dissolved at pH above 5.0.
    Type: Application
    Filed: July 11, 2014
    Publication date: July 7, 2016
    Inventors: Lars Hovgaard, Hanne Refsgaard, Thomas Boerglum Kjeldsen, Peter Madsen